Valvular & structural heart disease
Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis
Authors' conclusion
Our study demonstrated the prognostic significance of ePASP, rather than atrial fibrillation, in relation to MACE among patients with severe rheumatic MS.
Study context
- Population
- Patients with severe rheumatic mitral stenosis, 2006–2022
- Participants
- 287 patients
- Exposure
- ePASP >50 mm Hg vs ePASP ≤50 mm Hg
- Outcome
- MACE:
- All-cause mortality
- HF hospitalization
- Arterial thromboembolic events
- Follow-up
- Up to 5 years
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Adjusted hazard ratio (95% CI)P value
ePASP (per mm Hg, continuous)
1.027(1.011–1.042)
P < 0.001ePASP >45 mm Hgoptimal threshold by ROC analysis; independent predictor
2.127(1.424–3.177)
P < 0.001Per mm Hg, as printed
Observational data: associations, not effects.
Further findings
Echocardiographic parameters (mean mitral valve pressure gradient, mitral valve area, proportion with area <1.0 cm²)
- No differences between patients with and without major adverse cardiovascular events (MACE)
Original publication
Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis. Circ Cardiovasc Imaging. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →